Hong Kong suspends BioNTech vaccination due to packaging defects
HONG KONG, March 24 (Xinhua) -- The Hong Kong Special Administrative Region (HKSAR) government on Wednesday suspended the vaccination of BioNTech COVID-19 vaccine due to problems with their vial caps.
The HKSAR government made the decision on receiving a written notice from Fosun Pharma, saying the packaging problem of the vaccines of batch number 210102 has been noticed.
German drug manufacturer BioNTech and Fosun Pharma are the developers of the vaccine.
BioNTech and Fosun Pharma said no safety risk was found in the product, but they called for an immediate suspension of the vaccination in the interest of prudence until an investigation is completed.
The HKSAR government said that all community vaccination centers will suspend the vaccination of the vaccine until further notice.
It is reported that the Department of Health of the HKSAR government will hold an emergency meeting with Fosun on Wednesday to further understand and follow up the incident.
Photos
Related Stories
- Hong Kong can recover only by fully implementing "one country, two systems": HKSAR chief executive
- Chinese lawmakers to deliberate bills on amending HK electoral system on March 29-30
- HKSAR chief executive urges residents to actively receive COVID-19 vaccine
- Improving electoral system to rid Hong Kong of "political quagmire": HKSAR gov't official
- Hong Kong to reach new heights with full support of central authorities: HKSAR chief executive
- Over 2.38 mln signatures collected in Hong Kong for improving electoral system
- Central authorities heed advice on improving electoral system in HKSAR
- Central authorities hold multiple events in Hong Kong to heed advice on improving electoral system
- Decision to improving electoral system of HKSAR legal: law professor
- Interview: Financial market stability underpins Hong Kong as int'l financial hub
Copyright © 2021 People's Daily Online. All Rights Reserved.
